Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutDosing & Product InformationDosing and Product InformationDosing and StorageOrdering and CodingEfficacy & SafetyEfficacy and
SafetyClinical Data in Support of BiosimilaritySafety Data in Support of Biosimilarity Savings & Support Savings and SupportSupport and ResourcesCo-Pay AssistanceMaterialsPfizer Commitment
Full Prescribing InformationPatient InformationInstructions for Use Indication Patient SiteExplore the Biosimilars Portfolio
Ordering and Coding
Ordering NYVEPRIA® (pegfilgrastim-apgf)1-3
HCPCS=Healthcare Common Procedure Coding System; NDC=National Drug Code.*As of March 2025.Coding overview

The information provided below is intended for informational purposes only and is not a comprehensive description of potential coding requirements for NYVEPRIA. Coding and coverage policies change periodically and often without notice. The healthcare provider (HCP) is solely responsible for determining coverage and reimbursement parameters and appropriate coding for treatment of his/her patients. The information provided should not be considered a guarantee of coverage or reimbursement for NYVEPRIA.

In the physician office and hospital outpatient department sites of care, Medicare, Medicaid, and private commercial payers typically recognize the following codes for reporting NYVEPRIA and its administration on claim forms:

 CPT=Current Procedural Terminology.†For reimbursement purposes, some payers may require the HCP to include the NDC on the claim form in the 10-digit or 11-digit format.Diagnosis coding

The International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) code set should be used, as appropriate, to report the patient-specific diagnosis.

Reporting the medical necessity for NYVEPRIA may require a primary and secondary diagnosis in some cases. HCPs should verify payer-specific diagnosis coding and sequencing requirements before submitting a claim as they may vary by payer.

Dosing and Product Information Backed by the Pfizer commitment

With 15+ years of biosimilars experience globally, including more than 1.3 million people treated around the world2,5

 Learn More Loading Identifying financial support options. Together. Learn More LoadingQuick links cardReferences:NYVEPRIA [prescribing information]. New York, NY: Pfizer Inc.; March 2023.Data on file. Pfizer Inc.; New York, NY.CMS.gov. HCPCS Quarterly Update January 2023. Updated December 21, 2022. Accessed April 6, 2023. 
https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update.Synovec MS, Jagmin CL, Hochstetler Z, et al, eds. Medicine/hydration, injections & infusions. In: Synovec MS, Jagmin CL, Hochstetler Z, et al, eds. CPT® 2021 Professional Edition. American Medical Association; 2020:795-798.Generics and Biosimilars Initiative Online. Biosimilars approved in Europe. Updated July 1, 2022. Accessed May 23, 2023. https://gabionline.net/biosimilars/general/biosimilars-approved-in-europe.NYVEPRIA® (pegfilgrastim-apgf): is a registered trademark of Pfizer Inc.
CPT® is a registered trademark of the American Medical Association.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-NYV-USA-0019
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-PEG-USA-0169
INDICATIONNYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Limitations of Use
NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.Please see full Prescribing Information, Patient Information, and Instructions for Use for NYVEPRIA.
Important Safety Information

Contraindications

  • NYVEPRIA is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
  • Reactions have included anaphylaxis
Warnings and PrecautionsSplenic Rupture
  • Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products
  • Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving NYVEPRIA
Acute Respiratory Distress Syndrome (ARDS)
  • ARDS can occur in patients receiving pegfilgrastim products
  • Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving NYVEPRIA
  • Discontinue NYVEPRIA in patients with ARDS
Serious Allergic Reactions
  • Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products
  • The majority of reported events occurred upon initial exposure
  • Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti‐allergic treatment
  • Permanently discontinue NYVEPRIA in patients with serious allergic reactions
  • Do not administer NYVEPRIA to patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
Use in Patients with Sickle Cell Disorders
  • Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products
  • Discontinue NYVEPRIA if sickle cell crisis occurs
Glomerulonephritis
  • Glomerulonephritis has occurred in patients receiving pegfilgrastim products
  • The diagnoses were based on azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy
  • Generally, events of glomerulonephritis resolved after dose-reduction or discontinuation of pegfilgrastim products
  • If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of NYVEPRIA
Leukocytosis
  • White blood cell counts of 100 x 109/L or greater have been observed in patients receiving pegfilgrastim products
  • Monitoring of complete blood count (CBC) during NYVEPRIA therapy is recommended
Thrombocytopenia
  • Thrombocytopenia has been reported in patients receiving pegfilgrastim products
  • Monitor platelet counts
Capillary Leak Syndrome (CLS)
  • CLS has been reported after granulocyte-colony stimulating factor (G‐CSF) administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
  • Episodes vary in frequency and severity and may be life‐threatening if treatment is delayed
  • Patients who develop symptoms of CLS should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care
Potential for Tumor Growth Stimulatory Effects on Malignant Cells
  • The G-CSF receptor through which pegfilgrastim and filgrastim products act has been found on tumor cell lines
  • The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer
  • MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer
  • Monitor patients for signs and symptoms of MDS/AML in these settings
Aortitis
  • Aortitis has been reported in patients receiving pegfilgrastim products. It may occur as early as the first week after start of therapy
  • Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, c-reactive protein and white blood cell count)
  • Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue NYVEPRIA if aortitis is suspected
Nuclear Imaging
  • Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results
Most Common Adverse Reactions
  • Bone pain
  • Pain in extremity
Indication

NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use

NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Please see full Prescribing Information, Patient Information, and Instructions for Use for NYVEPRIA.